
|Articles|May 25, 2023
Pharmaceutical Executive's 2023 Emerging Pharma Leaders
Author(s)Pharmaceutical Executive Editors
Pharm Exec profiles its 2023 Emerging Pharma Leaders.
Advertisement
Each year, Pharmaceutical Executive recognizes up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry in the Emerging Pharma Leaders (EPL) Awards. Nominations are judged by three members of the Editorial Advisory Board as well as a former EPL representative. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with executives most likely to inhabit key “c-suite” functions.
The Pharm Exec team would like to congratulate the 2023 Emerging Pharma Leaders:
Natasha A. Hernday, chief business officer, Seagen Simon Holland, vice president, women's health commercial lead, Organon Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio Frank Watanabe, president and CEO, Arcutis Biotherapeutics Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics
To learn more about this year’s winners, you can also:
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5




